Interleukin-4-producing CD4+ T-cell (Th2 cell)

Interleukin-4-producing CD4+ T-cells, primarily represented by T-helper 2 (Th2) and T follicular helper (Tfh) subsets, are essential mediators of the adaptive immune system's type 2 response. These cells are characterized by the expression of the master transcription factor GATA3 and the secretion of signature cytokines such as IL-4, IL-13, and IL-5, which coordinate defenses against helminthic parasites and facilitate IgE-mediated immunity. However, their chronic or excessive activation is the fundamental driver of type 2 inflammatory diseases, including atopic dermatitis, allergic asthma, and chronic rhinosinusitis. While the cells themselves are not usually targeted for direct depletion, therapeutic strategies focus on blocking the molecular pathways they utilize. Modern biological therapies such as dupilumab target the IL-4 receptor alpha (IL-4Rα) to inhibit IL-4 and IL-13 signaling, while others target upstream activators like thymic stromal lymphopoietin (TSLP) to dampen the activation of these T-cell populations.

Other names

Th2 cellT-helper 2 cellIL-4+ CD4+ T-cellType 2 helper T-cellInterleukin-4-secreting T-cell

Inhibition of type 2 cytokine signaling pathways (IL-4Rα, IL-13Rα1) or upstream epithelial cytokines (TSLP, IL-33) to prevent the differentiation, recruitment, and effector function of these cells.